FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no FDA-approved…